Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
Cabozantinib is an inhibitor of tyrosine kinases, including MET,vascular endothelial growth factor receptor, AXLand RET. This multi-cohort phase II randomised discontinuation trialexplored anticancer activity of cabozantinib in nine tumour types.Cabozantinib was administered (100mg, once daily) to patients with advanced, recurrentor metastatic cancers. Those with stable disease at week 12 were randomised 1:1 to cabozantinib or placebo. Primary end-points were objective response rate (ORR) at week 12 and progression-free survival (PFS) in the randomised phase.A total of 526 patients were enroll... Mehr ...